Genotype distribution of Human Papillomavirus in women from Bogotá with abnormal cervical smear
Keywords:
Papanicolaou Test, Squamous Intraepithelial Lesions of the Cervix, Human Papillomavirus DNA TestsAbstract
Objective: To determine the distribution of HPV genotypes in women from Bogotá with abnormal cervical smear.
Methods: Cervical samples were collected from 191 women with ASCUS, 236 with low-grade (LSIL) and 116 with high-grade squamous intraepithelial lesions (HSIL). HPV typing was performed using consensus PCR primers GP5+/GP6 + and reverse line blot.
Results: The prevalence of HPV was 76.1%. Unique infections were observed in 41.4% of the participants and co-infections in 34.6%. The frequency of HPV according to diagnosis was: 60.2%, 84.7% and 84.5% in ASCUS, LSIL and HSIL respectively. HPV16 and 58 were the more frequent types in the three groups, HPV16 frequencies were 20.4%, 33.9% and 38.8%, and HPV58 frequencies were 7.3%, 13.6%, and 18,1% for ASCUS, LSIL and HSIL respectively. The third type in frequency in ASCUS and LSIL was HPV56 (6.8% and 11.0%), while in HSIL was HPV18 (10.3%). Infections with probably oncogenic types or with low risk types were much less frequent and generally were observed as co-infections with high-risk types.
Conclusions: Infections with high risk HPV types were the most frequent in all studied lesions, VPH-58 ranked second in frequency as has been reported in Mexico and in general in South America. The change to new prophylactic vaccines including more viral types as HPV58 could have a higher impact in reducing the incidence of pre-neoplastic lesions in our region.
Author Biographies
Esperanza Trujillo, Instituto Nacional de Cancerología
Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Nicolás Morales, Instituto Nacional de Cancerología
Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Oscar Buitrago, Instituto Nacional de Cancerología
Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Héctor Posso, Liga Contra el Cáncer-Bogotá
Dirección Médica, Liga Contra el Cáncer-Bogotá, Bogotá, D. C., Colombia
María Mercedes Bravo, Instituto Nacional de Cancerología
Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
References
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9.
https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048---56.
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009;10(4):321---2.
https://doi.org/10.1016/S1470-2045(09)70096-8
Wentzensen N, Nason M, Schiffman M, Dodd L, Hunt WC, Wheeler CM, et al. No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis. 2014;209(6):855---64.
https://doi.org/10.1093/infdis/jit577
Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1274---80.
Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011;203(7):910---20.
https://doi.org/10.1093/infdis/jiq139
Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26 Suppl 10:K1---16.
https://doi.org/10.1016/j.vaccine.2008.05.064
Clifford G, Franceschi S, Diaz M, Mu˜noz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24 Suppl 3. S3/26-34.
https://doi.org/10.1016/j.vaccine.2006.05.026
Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16(5):e206---16.
https://doi.org/10.1016/S1470-2045(14)70481-4
Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711---23.
https://doi.org/10.1056/NEJMoa1405044
van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40(3):779---87.
https://doi.org/10.1128/JCM.40.3.779-787.2002
Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, et al. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol. 2014;234(4):441---51.
https://doi.org/10.1002/path.4405
Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1157---64.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
